![Healing Nation Cbd Gummies: A Practical Look At Their Role In Daily Wellness [mlPjEnTxkY4]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/08/ced-pexels-6693918.jpg?resize=150%2C150&ssl=1 "Healing Nation Cbd Gummies: A Practical Look At Their Role In Daily Wellness [mlPjEnTxkY4] 26")
![Strawberry Cbd Gummies: A Practical Look At Taste, Effects, And Everyday Use [AsDivurPsHj]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/08/ced-pexels-9743242.jpg?resize=150%2C150&ssl=1 "Strawberry Cbd Gummies: A Practical Look At Taste, Effects, And Everyday Use [AsDivurPsHj] 29")
GLP-1 therapies- an emerging approach for alcohol reduction?
A recent study found that semaglutide significantly reduced heavy drinking days and alcohol craving in adults with alcohol use disorder and obesity, offering a promising new approach.
GLP‑1 Receptor Agonist Treatment and Health Outcomes in Methadone‑Treated Patien
GLP-1 receptor agonists significantly reduced myocardial infarctions, opioid overdoses, and suicidal ideation in methadone-treated OUD patients with T2D.
GLP‑1 Receptor Agonist Use Across Preconception, Pregnancy, and the Postpartum P
GLP-1 RA use in pregnancy remains controversial due to limited human data. This review synthesizes available evidence on risks and benefits across reproductive stages.
Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Ca
Semaglutide 2.4 mg significantly lowers the risk of heart attacks, strokes, and mortality in ASCVD patients with overweight or obesity. This study highlights its broad benefits beyond diabetes management.
Modes of cannabis administration, cannabis and tobacco co-use, and associations
This study highlights that adults who co-use cannabis with tobacco are more likely to use combustible methods, leading to worse respiratory outcomes and higher cannabis consumption.
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and
Semaglutide treatment led to a 13.7 percentage point reduction in heavy drinking days compared to placebo in patients with alcohol use disorder and obesity.
Repurposing semaglutide as an adjunctive treatment for cocaine use disorder- pro
Researchers are testing semaglutide as an adjunct to cognitive behavioral therapy for cocaine use disorder. This phase IIa trial aims to evaluate its efficacy and safety in reducing cocaine use and cravings.
Real-World Alcohol Use Disorder Outcomes in PatientsWith Concurrent Metabolic Dy
A recent study shows that GLP-1 receptor agonists are associated with a 45% lower rate of one-year AUD relapse compared to naltrexone in patients with concurrent metabolic dysfunction.
Real-World Cardiovascular Outcomes of ObesityTreatment With Tirzepatide Versus Semaglutide
Tirzepatide significantly reduces new-onset heart failure risk compared to semaglutide in obese, non-diabetic adults over 12 months
Medical Cannabis Education Has Not Kept Pace With Clinical Reality
Medical cannabis provider knowledge may be far weaker than many clinicians believe. A survey of 879 U.S. healthcare professionals found large gaps between self-rated confidence and objective cannabis knowledge. The findings raise important questions…